Epigenetic modulators as therapeutic targets in prostate cancer
Autor(a) principal: | |
---|---|
Data de Publicação: | 2016 |
Outros Autores: | , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10400.22/9336 |
Resumo: | Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management. |
id |
RCAP_1de9994ab7ef2a140ee8b4a4c10de23b |
---|---|
oai_identifier_str |
oai:recipp.ipp.pt:10400.22/9336 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Epigenetic modulators as therapeutic targets in prostate cancerProstate cancerDNMTiHistone modulatorsProstate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management.BioMed CentralRepositório Científico do Instituto Politécnico do PortoPinho dos Santos Graça, Maria InêsPereira-Silva, EvaHenrique, RuiPackham, GrahamCrabb, Simon J.Jerónimo, Carmen2017-01-20T15:09:15Z20162016-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10400.22/9336engGraça, I., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016). Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 8(1), 98. https://doi.org/10.1186/s13148-016-0264-81868-708310.1186/s13148-016-0264-8info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-12-27T01:48:11Zoai:recipp.ipp.pt:10400.22/9336Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T17:29:57.722274Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Epigenetic modulators as therapeutic targets in prostate cancer |
title |
Epigenetic modulators as therapeutic targets in prostate cancer |
spellingShingle |
Epigenetic modulators as therapeutic targets in prostate cancer Pinho dos Santos Graça, Maria Inês Prostate cancer DNMTi Histone modulators |
title_short |
Epigenetic modulators as therapeutic targets in prostate cancer |
title_full |
Epigenetic modulators as therapeutic targets in prostate cancer |
title_fullStr |
Epigenetic modulators as therapeutic targets in prostate cancer |
title_full_unstemmed |
Epigenetic modulators as therapeutic targets in prostate cancer |
title_sort |
Epigenetic modulators as therapeutic targets in prostate cancer |
author |
Pinho dos Santos Graça, Maria Inês |
author_facet |
Pinho dos Santos Graça, Maria Inês Pereira-Silva, Eva Henrique, Rui Packham, Graham Crabb, Simon J. Jerónimo, Carmen |
author_role |
author |
author2 |
Pereira-Silva, Eva Henrique, Rui Packham, Graham Crabb, Simon J. Jerónimo, Carmen |
author2_role |
author author author author author |
dc.contributor.none.fl_str_mv |
Repositório Científico do Instituto Politécnico do Porto |
dc.contributor.author.fl_str_mv |
Pinho dos Santos Graça, Maria Inês Pereira-Silva, Eva Henrique, Rui Packham, Graham Crabb, Simon J. Jerónimo, Carmen |
dc.subject.por.fl_str_mv |
Prostate cancer DNMTi Histone modulators |
topic |
Prostate cancer DNMTi Histone modulators |
description |
Prostate cancer is one of the most common non-cutaneous malignancies among men worldwide. Epigenetic aberrations, including changes in DNA methylation patterns and/or histone modifications, are key drivers of prostate carcinogenesis. These epigenetic defects might be due to deregulated function and/or expression of the epigenetic machinery, affecting the expression of several important genes. Remarkably, epigenetic modifications are reversible and numerous compounds that target the epigenetic enzymes and regulatory proteins were reported to be effective in cancer growth control. In fact, some of these drugs are already being tested in clinical trials. This review discusses the most important epigenetic alterations in prostate cancer, highlighting the role of epigenetic modulating compounds in pre-clinical and clinical trials as potential therapeutic agents for prostate cancer management. |
publishDate |
2016 |
dc.date.none.fl_str_mv |
2016 2016-01-01T00:00:00Z 2017-01-20T15:09:15Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10400.22/9336 |
url |
http://hdl.handle.net/10400.22/9336 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Graça, I., Pereira-Silva, E., Henrique, R., Packham, G., Crabb, S. J., & Jerónimo, C. (2016). Epigenetic modulators as therapeutic targets in prostate cancer. Clinical Epigenetics, 8(1), 98. https://doi.org/10.1186/s13148-016-0264-8 1868-7083 10.1186/s13148-016-0264-8 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
BioMed Central |
publisher.none.fl_str_mv |
BioMed Central |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799131395795189760 |